SLU-PP-332: The Exercise Mimetic Compound Rewriting Muscle Biology

SLU-PP-332 is a small molecule that activates the estrogen-related receptor (ERR) family — specifically ERRα, ERRβ, and ERRγ. It was developed by researchers at Washington University in St. Louis (hence "SLU") under Dr. Thomas Burris.

It is technically not a peptide (it is a small molecule, not an amino acid chain). However, it is widely discussed in peptide research communities. It targets the same molecular pathways as growth hormone-releasing peptides and metabolic peptides. It is also often sourced from peptide research suppliers.

The "exercise mimetic" label reflects SLU-PP-332's ability to activate gene expression programs that normally only turn on during physical exercise. During endurance training, muscles undergo a coordinated response involving hundreds of genes. These genes enhance oxidative metabolism, mitochondrial growth, fatty acid oxidation, and fatigue resistance.

ERR proteins are master transcription factors that orchestrate much of this response. SLU-PP-332 activates these ERR proteins directly. This bypasses the need for physical and metabolic stress to trigger these changes.

A landmark 2023 study in Nature by Xia et al. showed that SLU-PP-332 produced striking exercise-like changes in mice. These included increased oxidative muscle fiber content, enhanced endurance, and improved metabolic profiles — all without any change in physical activity.

These findings drew major scientific and media attention. SLU-PP-332 is now a leading candidate in the "exercise in a pill" research space. For context on how research compounds interact with metabolic pathways, see our peptide fundamentals guide.

Understanding SLU-PP-332 requires understanding the ERR family of nuclear receptors and their central role in exercise physiology.

Estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors. They are transcription factors named for their structural similarity to estrogen receptors — but they do not bind estrogen. Despite the confusing naming, ERRs work independently of estrogen signaling. They are always-active transcription factors that regulate genes for energy metabolism, mitochondrial function, and muscle fiber type.

ERRα: Found in nearly all tissues, ERRα is the primary metabolic regulator in the ERR family. It controls genes involved in:

• Fatty acid oxidation (CPT1B, ACADM, ACADL)
• The tricarboxylic acid cycle (IDH3A, ACO2)
• Oxidative phosphorylation (NDUFS1, SDHA, COX5A)
• Mitochondrial growth (TFAM, NRF1)

Exercise raises ERRα expression and activity. This explains many of exercise's metabolic benefits.

ERRβ: Less studied than ERRα, ERRβ plays roles in stem cell maintenance and early development. It also contributes to metabolic gene regulation in skeletal muscle. ERRβ knockout mice show impaired oxidative capacity, suggesting a supporting role in exercise adaptation.

ERRγ: Highly expressed in oxidative tissues including the heart, kidneys, and slow-twitch (Type I) muscle fibers. ERRγ is a key factor in muscle fiber type — its levels directly correlate with oxidative fiber content. Mice overexpressing ERRγ in skeletal muscle develop "marathon mouse" traits. These include dramatically increased endurance, enhanced fat oxidation, and resistance to diet-induced obesity.

SLU-PP-332 is a pan-ERR agonist that activates all three family members at once. This broad activation mirrors the full transcriptional response to exercise rather than targeting one component. The compound binds to the ligand-binding domain of ERR proteins.

It stabilizes them in an active form that boosts transcription of target genes. For more on how molecular interventions can affect metabolic pathways, explore our muscle growth peptide guide.

The 2023 study by Xia et al. in Nature provided the most compelling evidence for SLU-PP-332's exercise-mimetic traits. The key findings deserve a close look.

Muscle Fiber Type Conversion: Mice treated with SLU-PP-332 (50 mg/kg intraperitoneally, twice daily for 28 days) showed a major shift in muscle fiber makeup. Glycolytic (Type IIb/IIx) fibers shifted toward oxidative (Type I and Type IIa) fibers. In the soleus and gastrocnemius muscles, oxidative fiber content rose by 40-60% versus controls.

This fiber type shift matches what happens with chronic endurance training. That change normally requires weeks to months of steady aerobic exercise.

Enhanced Endurance: Treadmill testing showed that SLU-PP-332-treated mice ran about 50% longer and 45% farther than controls before exhaustion. This happened without any change in daily activity — the mice were sedentary, yet performed as if endurance-trained. Running economy (distance per unit energy spent) also improved. This suggests real metabolic efficiency gains, not just increased pain tolerance.

Metabolic Improvements: Treated mice showed increased whole-body fatty acid oxidation and reduced respiratory exchange ratio (meaning greater fat use). Glucose tolerance also improved. Gene expression profiling in skeletal muscle revealed over 500 upregulated genes for oxidative metabolism, mitochondrial growth, and fatty acid transport. This gene signature was nearly identical to that produced by endurance exercise.

Resistance to Muscle Wasting: In a high-fat diet model, SLU-PP-332 partially prevented the drop in muscle quality and oxidative capacity that obesity typically causes. Treated mice on high-fat diets kept 73% of their baseline treadmill performance. Untreated controls kept only 41%. This suggests protective effects against obesity-induced muscle problems.

Body Composition Effects: SLU-PP-332-treated mice on high-fat diets gained 10% less body weight than controls. The difference came from reduced fat mass, not lean mass changes. The modest weight effect suggests SLU-PP-332's main benefits are metabolic efficiency and muscle quality rather than direct fat loss.

SLU-PP-332 is not the first compound studied as an exercise mimetic. Comparing it to earlier compounds provides key research context.

SLU-PP-332 vs. GW501516 (Cardarine): GW501516 is a PPARδ agonist — one of the earliest compounds called an "exercise mimetic." It boosts fatty acid oxidation and endurance through PPARδ-mediated gene expression. However, development was abandoned due to cancer concerns in preclinical studies. Specifically, it sped up tumor growth in multiple organ systems during long-term animal studies.

SLU-PP-332 targets a different pathway (ERR vs. PPAR). It has not shown cancer signals in published studies. However, long-term safety data is limited to current preclinical timeframes.

SLU-PP-332 vs. AICAR: AICAR activates AMP-activated protein kinase (AMPK), the cellular energy sensor that triggers exercise-like metabolic changes. While AICAR raises endurance in animal models, it has drawbacks:

• It requires intravenous dosing
• Oral bioavailability is poor
• Effects are relatively modest versus SLU-PP-332
• AMPK activation can be counterproductive — including excessive autophagy in some contexts

SLU-PP-332 vs. Irisin/FNDC5: Irisin is a muscle-secreted hormone released during exercise. It promotes browning of white fat tissue. While irisin copies one specific exercise effect (thermogenic fat conversion), SLU-PP-332's pan-ERR activation produces a much broader response. This includes muscle fiber type conversion, mitochondrial growth, and broad metabolic reprogramming.

SLU-PP-332's advantage lies in targeting upstream master regulators (ERRs) rather than individual downstream pathways. This produces a more complete exercise-like response. However, the effects are also broad and potentially harder to control precisely. Research listings (third-party retailers—we don't verify compounds).

The ability to turn on exercise pathways with a compound has major implications for people unable to exercise normally.

Muscle Wasting Diseases: Conditions like muscular dystrophy, sarcopenia (age-related muscle loss), cancer cachexia, and prolonged bed rest involve progressive loss of oxidative muscle fibers and mitochondrial function. These are exactly the pathways SLU-PP-332 activates.

If exercise-mimetic compounds can maintain or restore oxidative muscle capacity in those unable to exercise, the impact would be large. Sarcopenia alone affects 10-16% of adults over 60. Annual healthcare costs exceed $40 billion in the United States.

Metabolic Disease: Type 2 diabetes, obesity, and metabolic syndrome all involve impaired oxidative metabolism and mitochondrial problems in skeletal muscle. Exercise is the most effective treatment for these conditions.

But adherence rates are very low — only 20-30% of study participants maintain prescribed exercise programs. SLU-PP-332 could provide metabolic benefits to those who cannot exercise enough due to physical limits, mobility issues, or severe obesity.

Heart Failure: ERRα and ERRγ are critical regulators of cardiac metabolism. Heart failure involves a metabolic shift from fatty acid oxidation to inefficient glucose use in heart muscle cells. ERR activation could theoretically restore cardiac metabolic efficiency. This might improve contractile function and exercise tolerance.

Spinal Cord Injury and Immobilization: Spinal cord injury patients cannot activate skeletal muscles below the injury level. This leads to rapid muscle wasting and metabolic problems. An exercise mimetic that activates muscle metabolic programs without neural-driven contraction could preserve muscle quality in these groups.

Spaceflight Physiology: Microgravity causes rapid muscle wasting and metabolic problems in astronauts, despite current exercise routines. NASA has shown interest in drug-based additions to exercise for long-duration missions. For more on metabolic research compounds, see our article on SS-31 peptide and mitochondrial function.

SLU-PP-332 remains in early-stage research. Several important limitations temper the excitement around its exercise-mimetic traits.

Preclinical Data Only: All published data comes from mouse and cell culture studies. No human clinical trials have been run or, as of early 2026, publicly registered. Translation from mouse to human exercise physiology is not guaranteed.

While the ERR pathway is conserved between species, differences in muscle fiber makeup, metabolic rate, and drug metabolism could greatly alter the effects in humans.

Dosing Route Challenges: The published mouse studies used intraperitoneal injection at 50 mg/kg twice daily. This is a high dose and an impractical route for human use. Oral bioavailability data has not been published. Developing an oral formulation at useful doses remains a major challenge.

Limited Safety Data: While 28-day preclinical studies showed no obvious toxicity, the long-term safety profile of ERR activation is unknown. ERR proteins regulate gene expression in many tissues beyond muscle, including the heart, liver, kidneys, and brain. Chronic pan-ERR activation could have unintended effects in these tissues. Full toxicology studies are needed before human testing.

Not a Complete Exercise Replacement: Even if SLU-PP-332 perfectly copies the metabolic and muscular changes from exercise, it cannot reproduce other exercise benefits:

• Cardiovascular conditioning
• Bone loading (preventing osteoporosis)
• Neuroplasticity
• Psychological well-being
• Social engagement

Any clinical application would likely position exercise mimetics as additions to, rather than replacements for, physical activity.

Intellectual Property and Development Path: SLU-PP-332's path from academic research to clinical use remains unclear. No pharmaceutical company has publicly announced licensing or development plans for it specifically. However, multiple companies are pursuing ERR-targeted approaches. The timeline to potential clinical availability is likely years, not months.

SLU-PP-332 is part of a growing field of exercise mimetic research. Scientific interest in activating exercise pathways with compounds is rising fast.

Molecular Targets Under Study: Beyond ERR activation, researchers are pursuing AMPK activators, PGC-1α pathway modulators, myokine analogs (irisin, meteorin-like, BAIBA), mitochondria-targeted compounds, and sirtuin activators. Each approach mimics a different facet of exercise adaptation.

The eventual clinical strategy may involve combination regimens targeting multiple pathways at once — much like how actual exercise activates hundreds of molecular programs at the same time.

NAD+ Precursors: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors. They support mitochondrial function and sirtuin activity — key parts of the exercise response. While not exercise mimetics in the strict sense, NAD+ supplementation produces some overlapping metabolic benefits. Learn more in our NAD+ peptide research guide.

Regulatory and Ethical Considerations: Exercise mimetics raise important questions about athletic doping, fair access, and the treatment of sedentary lifestyles as medical conditions. WADA has already banned GW501516 and AICAR.

They would likely move fast to ban any effective exercise mimetic. The ethical debate — whether providing metabolic benefits to those who cannot exercise differs from enhancing already-healthy athletes — mirrors existing discussions around peptide therapy regulation.

Integration with Peptide Research: SLU-PP-332's pathways overlap with several established peptide research areas. Growth hormone-releasing peptides and IGF-1-modulating compounds influence many of the same muscle growth and metabolic pathways. Mitochondria-targeted peptides like SS-31 address the mitochondrial growth component.

The convergence of small molecule exercise mimetics with peptide-based metabolic modulators may define the next generation of metabolic research compounds. For ongoing developments, visit our peptide therapy guide.

For researchers interested in SLU-PP-332, several practical factors deserve attention.

Sourcing: SLU-PP-332 is available from specialized research chemical suppliers, though availability is more limited than established peptides. When sourcing, verify the supplier provides HPLC purity data (≥95% for small molecules), mass spectrometry identity confirmation, and batch-specific certificates of analysis. The compound's chemical structure (molecular formula C26H23FN2O3S, MW 462.53) should be confirmed by the supplier's analytical data.

Solubility and Preparation: SLU-PP-332 typically comes as a powder. It requires dissolution in DMSO for in vitro work or formulation in suitable vehicles for in vivo studies. The published mouse studies used intraperitoneal injection in a vehicle of 10% DMSO/90% corn oil. Researchers should verify solubility and stability in their specific conditions.

Dosing Translation: The 50 mg/kg dose used in mouse studies does not translate directly to human doses. Using standard allometric scaling (FDA guidance), the mouse dose would correspond to about 4 mg/kg in humans. That is roughly 280-320 mg for a 70-80 kg adult. This calculation is preliminary. Actual human dosing would require formal pharmacokinetic studies.

Experimental Controls: Exercise mimetic research requires careful experimental design. Positive controls should include an exercise group (treadmill running, swimming) to benchmark SLU-PP-332 against actual exercise. Pathway-specific readouts should be included alongside functional outcomes:

• ERR target gene expression (CPT1B, ACADM, TFAM, COX5A)
• Fiber type immunohistochemistry
• Mitochondrial enzyme activity assays

All research protocols should include proper institutional oversight and follow applicable regulatory guidelines. See about for how PurePep discusses retailer documentation (we don’t test products).